Hofseth Biocare (HBC) announces the issuance of a Notice of Allowance of its co-developed Canadian Patent 2,743,434 on A METHOD OF LOWERING CIRCULATING OXIDIZED LOW DENSITY LIPOPROTEIN-BETA-2-GLYCOPROTEIN 1 COMPLEX FOR TREATMENT OF ATHEROSCLEROSIS.
Atherosclerosis is a disease characterized by the deposition of plaques of fatty material on the coronary arteries' inner walls, and usually develops over many years. This is the underlying cause of most heart attacks today.
This intellectual property grant will accelerate HBC's expansion into the Canadian market with its own labeled finished products and full intellectual property protection.
For more information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mob.: +47 93632966
Email: joo@h-bc.no
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.